Cablivi

Cablivi (caplacizumab) is a medication used to manage certain blood clotting disorders. This intravenous or subcutaneous treatment helps reduce the risk of clotting complications in specific patient populations.

Cablivi is primarily used to manage acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. It works by inhibiting von Willebrand factor, which helps prevent the formation of blood clots. Patients typically use Cablivi under medical supervision to reduce the frequency of clotting events and improve overall blood flow.

Common effects of Cablivi may include bleeding or bruising at the injection site. Some users might experience mild to moderate nosebleeds or gum bleeding. Severe bleeding is rare but possible, and any unusual bleeding should be reported to a healthcare provider immediately.

Cablivi should be handled with care, especially by individuals with a history of bleeding disorders. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their doctor about any other medications they are taking to avoid potential interactions.

Cablivi may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Alcohol and certain supplements might also influence its effectiveness. Always consult a healthcare provider before combining Cablivi with other treatments.